NCT06433128Available不适用
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections Who Have no Other Treatment Options
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant PatientsSolid Organ Transplant RejectionOrgan Rejection TransplantsOrgan RejectionNCT05215288Direct Biologics, LLC
Approved For Marketing
不适用
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNCT04599712Janssen Research & Development, LLC
No Longer Available
不适用
Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment OptionsSickle Cell DiseaseNCT04724421Pfizer
No Longer Available
不适用
Expanded Access to FosigotifatorVanishing White MatterCree LeukoencephalopathyNCT06594016AbbVie
Available
不适用
Expanded Access to MepseviiMucopolysaccharidosis VIISly SyndromeMPS VIINCT03775174Ultragenyx Pharmaceutical Inc